Efficacy and safety of dabigatran etexilate vs. Warfarin in asian RE-LY patients according to baseline renal function or CHADS2 score

Circulation Journal

Volumn 79, Issue 10, 2015, Pages 2138-2147

  Hori, Masatsugu ^a   Fukaya, Taku ^b   Kleine, Eva ^c   Reilly, Paul A ^d   Ezekowitz, Michael D ^e   Connolly, Stuart J ^f  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Asians; CHADS2 score; Dabigatran; RE LY; Renal function

Indexed keywords

DABIGATRAN ETEXILATE; WARFARIN; CREATININE; DABIGATRAN;

ADULT; ARTICLE; BLEEDING; CARDIOEMBOLIC STROKE; CHADS2 SCORE; CLINICAL EVALUATION; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; HEMORRHAGE; KIDNEY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STROKE; URINE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CREATININE; DABIGATRAN; EMBOLISM; FEMALE; HEMORRHAGE; HUMANS; KIDNEY; MALE; MIDDLE AGED; STROKE; WARFARIN;

EID: 84942532121     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0594     Document Type: Article

References (21)

1. Inoue H. Thromboembolism in patients with nonvalvular atrial fibrillation: Comparison between Asian and Western countries. J Cardiol 2013; 61: 1 –7.
2. Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int J Cardiol 2009; 137: 102 – 107.
3. Ogawa S, Hori M. Urgent statement on antithrombotic therapy of atrial fibrillation. Circ J 2011; 75: 2719 – 2721.
4. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: A report from the J-RHYTHM Registry. Circ J 2011; 75: 1328 – 1333.
5. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. Circ J 2014; 78: 1997 – 2021.
6. Apostolakis S, Guo Y, Lane DA, Buller H, Lip GY. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: The AMADEUS trial. Eur Heart J 2013; 34: 3572 – 3579.
7. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367: 625 – 635.
8. Boehringer Ingelheim. Press release archive: SPAF. http://www. boehringer-ingelheim.com/news/news_releases/press_releases/ 2014/06_march_2014_dabigatranetexilate.html(accessed December 12, 2014).
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139 – 1151.
10. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al. Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44: 1891 – 1896.
11. Yasaka M, Lip GY. Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation. Circ J 2014; 78: 2367 – 2372.
12. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363 – 2372.
13. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial. Ann Intern Med 2011; 155: 660 – 667.
14. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875 – 1876.
15. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387 – 2394.
16. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363 – 1369.
17. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821 – 2830.
18. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Oncedaily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013; 127: 224 – 232.
19. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129: 961 – 970.
20. Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry. J Cardiol 2013; 61: 260 – 266.
21. Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, et al; SAMURAI Study Investigators. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI-NVAF Study. Int J Stroke 2015; 10: 836 – 842.